Our consultants cover a wide range of cancer types and are up-to-date with all the latest treatments and therapies. They work closely with our practice team to ensure that every step of the process is seamless and stress free.
Our expert consultants will carry out a detailed process of assessment and investigation before deciding on the best treatment plan for you. This may include:
Qualifications: BsC Hons, MB ChB, MRCP, FRCR
Special Interests: CNS tumours, paediatric tumours, brain metastases, oligo-metastases, stereotactic radiotherapy, proton therapy
After completing his training as a specialist registrar in Clinical Oncology at the Christie, Dr Colaco was selected as the first UK doctor to train in proton therapy spending 12 months working in proton therapy at the University of Florida Proton Therapy Institute in Jacksonville, Florida.
He was subsequently the first graduate of the Stereotactic Radiosurgery and Radiotherapy program at Yale University in Connecticut, USA, where he worked with a variety of radiotherapy delivery platforms including the Cyberknife, Gammaknife and Novalis TX treating patients with stereotactic radiosurgery(SRS) for brain metastases and stereotactic ablative radiotherapy (SABR) for both primary lung tumours and oligo-metastatic disease from other primary cancer sites.
Following his return from the United States, he was appointed as a consultant clinical oncologist at The Christie where he specialises in the treatment of adult brain tumours and paediatric tumours along with stereotactic radiotherapy for brain metastases and oligo-metastases.
He also sees patients for proton therapy and is involved in the development of The Christie proton beam centre and in the Christie program for oligo-metastatic disease including treating tumours which have metastasised to bone, spine and lymph nodes with SABR.
He is the principal investigator at the Christie for the CORE trial which is examining the role of stereotactic radiotherapy in oligo-metastatic breast, lung and prostate cancers.
Qualifications: BMedSci, MBChB, MRCP (UK), FRCR, MSc, MD(res)
Special Interests: Treatment of Breast and Lung Cancer stereotactic radiotherapys and proton radiotherapy
Dr Woolf is a graduate of the University of Birmingham. Core medical and Clinical Oncology training was in London (University College Hospital, The Royal Free and St Bartholomews’). A Master’s Degree in Oncology at the Institute of Cancer Research and a Doctorate of Medicine after research at Mount Vernon Cancer Centre.
Dr Woolf has a particular interest in the development of high-quality health care participating as a member of the Keogh Quality of Care Review Inspections Panel and as Clinical Expert in Care Quality Commission (CQC) inspections.
During his career, Dr Woolf has had over 20 publications in peer-reviewed journals and published book chapters as well as over 40 oral and poster presentations to national and international conferences. These include multiple publications and presentations in the field of breast and lung cancer.
Dr Woolf plans and delivers radiotherapy at The Christie to patients with breast and lung cancers and also gives Stereotactic Ablative Radiotherapy (SABR) for lung cancers and oligometastases (cancers that have spread to the lungs). In addition, he gives hormone therapy (endocrine therapy), chemotherapy and targeted drugs.
Qualifications: MB ChB, PGCert, MSc, PhD, FHEA, FESTRO, FRCR
Dr. Salem is a Senior Clinical Fellow in Lung Cancer Research at the University of Manchester and an Honorary Consultant in Clinical Oncology at The Christie NHS Foundation Trust, UK.
Clinically specializing in lung cancer radiotherapy, Dr. Salem’s research focuses on proton radiotherapy and the MR Linac, novel trials, biomarkers and hypoxia.
Dr. Salem has completed training in radiation oncology at King Hussein Cancer Centre (Amman, Jordan) in 2014, attaining fellowships and specialty certifications in clinical (FRCR), radiation (ESTRO fellowship & Jordanian board) and medical oncology (MRCP medical oncology & ESMO certification). Dr. Salem also completed a CRUK/EPSRC funded clinical research fellowship in 2017, attaining a PhD in Medicine from the University of Manchester for research focusing on non-invasive therapeutic lung cancer biomarkers.
Dr. Salem has successfully delivered several world-class clinical/ translational studies in lung cancer patients, publishing more than 50 peer-reviewed papers and many abstracts, posters and proceedings in eminent oncology conferences. Dr. Salem is a recipient of more than 10 prestigious academic oncology awards such as the ESTRO Accuray Award and the ASTRO International-US annual meeting scientific abstract award.
Apart from research, Dr. Salem is a keen educationalist. He is the current director of ESTRO FALCON lung cancer contouring workshops and supervisors a number of MSc and PhD students.
Dr. Salem’s career goal is to lead an innovative lung cancer advanced radiotherapy research portfolio, aiming to deliver survival and quality-of-life improvements for lung cancer patients.